AR101840A1 - ANTIGENS OF THE HUMAN PAPILOMA VIRUS HIGHER WITH HIGHER IMMUNE PROPERTIES, AND VACCINE THAT CONTAINS THEM - Google Patents

ANTIGENS OF THE HUMAN PAPILOMA VIRUS HIGHER WITH HIGHER IMMUNE PROPERTIES, AND VACCINE THAT CONTAINS THEM

Info

Publication number
AR101840A1
AR101840A1 ARP150102901A ARP150102901A AR101840A1 AR 101840 A1 AR101840 A1 AR 101840A1 AR P150102901 A ARP150102901 A AR P150102901A AR P150102901 A ARP150102901 A AR P150102901A AR 101840 A1 AR101840 A1 AR 101840A1
Authority
AR
Argentina
Prior art keywords
protein
human papillomavirus
seq
gene
gene encoding
Prior art date
Application number
ARP150102901A
Other languages
Spanish (es)
Inventor
Glueck Reinhard
Giannino Viviana
Gupta Gaurav
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AR101840A1 publication Critical patent/AR101840A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un gen aislado que codifica la proteína de la cápside mayor del virus del papiloma humano, caracterizado porque dicho gen se selecciona entre SEQ ID Nº 2, SEQ ID Nº 3, SEQ ID Nº 4 y SEQ ID Nº 5. Reivindicación 2: Un vector que comprende el gen que codifica la proteína de la cápside mayor del virus del papiloma humano, caracterizado porque dicho gen se selecciona entre SEQ ID Nº 2, SEQ ID Nº 3, SEQ ID Nº 4, SEQ ID Nº 5, y su combinación. Reivindicación 6: Una célula huésped caracterizada porque comprende el vector tal como se reivindica en la reivindicación 2. Reivindicación 11: Una vacuna contra el virus del papiloma humano, caracterizada porque comprende al menos un gen que codifica la proteína del cápside entre las reivindicadas en la reivindicación 1, que puede generar una respuesta inmunitaria contra el antígeno del HPV. Reivindicación 16: Un método para preparar la vacuna contra el virus del papiloma humano tal como se reivindica en la reivindicación 11, caracterizado porque comprende los siguientes pasos: a) síntesis del gen que codifica la proteína de la cápside mayor del virus del papiloma humano; b) construcción del vector de expresión para el gen que codifica la proteína de la cápside mayor del virus del papiloma humano; c) selección del clon con un número alto de copias del gen transformado de dicha proteína del virus del papiloma humano; d) análisis de expresión del gen transformado de dicha proteína del virus del papiloma humano; e) purificación de la proteína codificada por el gen de dicha proteína del virus del papiloma humano; f) preparación de solución a granel de VLPs de dicha proteína del virus del papiloma humano; g) caracterización de dicha proteína en la célula huésped; h) preparación de la vacuna que contiene dicha proteína del virus del papiloma humano.Claim 1: An isolated gene encoding the major capsid protein of the human papillomavirus, characterized in that said gene is selected from SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4 and SEQ ID No. 5. Claim 2: A vector comprising the gene encoding the protein of the major capsid of the human papillomavirus, characterized in that said gene is selected from SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, and their combination . Claim 6: A host cell characterized in that it comprises the vector as claimed in claim 2. Claim 11: A vaccine against the human papillomavirus, characterized in that it comprises at least one gene encoding the capsid protein between those claimed in the claim 1, which can generate an immune response against the HPV antigen. Claim 16: A method for preparing the vaccine against the human papillomavirus as claimed in claim 11, characterized in that it comprises the following steps: a) synthesis of the gene encoding the major capsid protein of the human papillomavirus; b) construction of the expression vector for the gene encoding the major capsid protein of the human papillomavirus; c) selection of the clone with a high copy number of the transformed gene of said human papillomavirus protein; d) expression analysis of the transformed gene of said human papillomavirus protein; e) purification of the protein encoded by the gene of said human papillomavirus protein; f) preparation of bulk solution of VLPs of said human papillomavirus protein; g) characterization of said protein in the host cell; h) preparation of the vaccine containing said human papillomavirus protein.

ARP150102901A 2014-09-11 2015-09-11 ANTIGENS OF THE HUMAN PAPILOMA VIRUS HIGHER WITH HIGHER IMMUNE PROPERTIES, AND VACCINE THAT CONTAINS THEM AR101840A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2905MU2014 2014-09-11

Publications (1)

Publication Number Publication Date
AR101840A1 true AR101840A1 (en) 2017-01-18

Family

ID=54843870

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102901A AR101840A1 (en) 2014-09-11 2015-09-11 ANTIGENS OF THE HUMAN PAPILOMA VIRUS HIGHER WITH HIGHER IMMUNE PROPERTIES, AND VACCINE THAT CONTAINS THEM

Country Status (10)

Country Link
EP (1) EP3191505A2 (en)
JP (1) JP2017528137A (en)
CN (1) CN107002085A (en)
AR (1) AR101840A1 (en)
AU (1) AU2015313756A1 (en)
BR (1) BR112017004181A2 (en)
CA (1) CA2958222A1 (en)
EA (1) EA201790365A1 (en)
MA (1) MA40624A (en)
WO (1) WO2016038625A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117187262A (en) * 2014-02-18 2023-12-08 上海泽润生物科技有限公司 Recombinant human papilloma virus protein expression
SG11201803209QA (en) 2015-10-19 2018-05-30 Cadila Healthcare Ltd New adjuvant and vaccine composition containing the same
CN109750049B (en) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 Recombinant human papillomavirus subtype 52 protein expression
JP2021502822A (en) * 2017-11-14 2021-02-04 フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． Non-human papillomavirus for gene delivery in vitro and in vivo
BR102020006846A2 (en) * 2020-04-03 2021-12-07 Imunoscan Engenharia Molecular Ltda SYNTHETIC PEPTIDES MIMETIC TO HPV L1 PROTEIN, HPV DIAGNOSIS METHOD, HPV DIAGNOSIS SYSTEM, PHARMACEUTICAL COMPOSITION AND USE THEREOF IN HPV TREATMENT OR PROPHYLAXIS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69631380T2 (en) * 1995-11-15 2004-11-04 Merck & Co., Inc. SYNTHETIC HPV11 VIRUS-LIKE PARTICLES
WO1998044944A2 (en) * 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
EP1700911B1 (en) * 1997-09-05 2016-04-06 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
JP4769247B2 (en) * 2004-06-18 2011-09-07 インディアン・イムノロジカルズ・リミテッド Codon optimized HPV16L1 for Salmonella vaccine strain against human papillomavirus type 16
CN101487009B (en) * 2008-01-15 2012-11-21 上海泽润生物科技有限公司 Method for preparing vaccine for anti-HPV 16 infection by pichia yeast expression system
CN101835797A (en) * 2007-11-23 2010-09-15 上海泽润生物科技有限公司 Human papilloma virus major capsid protein L 1 gene and uses thereof
BRPI0916732B1 (en) * 2008-07-31 2021-06-29 Glaxosmithkline Biologicals S.A. VACCINE FOR THE PREVENTION OF DISEASE OR INFECTION RELATED TO HUMAN PAPILLOMAVIRUS (HPV) COMPRISING PARTICLES SIMILAR TO THE HPV 16 AND HPV 18 VIRUSES
PL2444103T3 (en) * 2009-06-19 2018-05-30 Eyegene Inc. Vaccine for cervical cancer
CN102154325B (en) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 Vaccine against human papillomavirus (HPV) as well as preparation method and application thereof
BR112013029143A2 (en) * 2011-05-13 2017-07-11 Folia Biotech Inc in vitro process for the preparation of virus-like particles and their use, papaya mosaic virus-like virus particle, pharmaceutical composition and method for enhancing an immune response to an antigen and for stimulating the innate immune response in an individual
ES2762230T3 (en) * 2011-06-24 2020-05-22 Merck Sharp & Dohme HPV vaccine formulations comprising an aluminum adjuvant and production methods thereof
KR101559622B1 (en) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 An Efficient Method for Purifying Virus-Like Particles of Human Papillomavirus
CN103667319B (en) * 2012-09-10 2017-09-26 同济大学 The trivalent vaccine and its preparation method and purposes of anti-human papilloma virus (anti-HPV)

Also Published As

Publication number Publication date
EP3191505A2 (en) 2017-07-19
BR112017004181A2 (en) 2017-12-05
AU2015313756A1 (en) 2017-03-09
EA201790365A1 (en) 2017-07-31
MA40624A (en) 2016-03-17
WO2016038625A3 (en) 2016-04-28
WO2016038625A2 (en) 2016-03-17
JP2017528137A (en) 2017-09-28
CN107002085A (en) 2017-08-01
CA2958222A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
AR101840A1 (en) ANTIGENS OF THE HUMAN PAPILOMA VIRUS HIGHER WITH HIGHER IMMUNE PROPERTIES, AND VACCINE THAT CONTAINS THEM
CO2018005265A2 (en) Nucleic acid vaccines for varicella-zoster virus
MX2013008836A (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof.
PH12017500727A1 (en) Modified virus-like particles of cmv
PH12015502790A1 (en) Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof
MX2019012223A (en) Anti-cd137 antibodies and methods of use thereof.
EA201201025A1 (en) NUCLEIC ACID MOLECULES OF INFLUENZA AND VACCINES PRODUCED FROM THEM
AR102006A1 (en) RECOMBINANT VACCINES AGAINST THE VIRUS OF AFTOSE FEVER (FMDV) AND ITS USES
PH12019500591A1 (en) Canine adenovirus vectors
AR101468A1 (en) ADENOVIRUS AVIAR SEROTYPE RECOMBINING VECTOR VACCINE 9
PH12019500578A1 (en) New promoters
PH12019500557A1 (en) New ehv insertion site orf70
CY1118704T1 (en) HUMAN CATHERINE CYLINDER BLAST POPULATION POPULATION AND ITS USES
NZ759538A (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
PH12020500526A1 (en) Paramyxoviridae expression system
MX2019007924A (en) Influenza vaccines.
EA202092164A1 (en) NEW EHV WITH INACTIVATED UL18 AND / OR UL8
AR092939A1 (en) VACCINE AGAINST COOPERIA
WO2012001196A3 (en) Propagative alphaviral expression vectors not forming functional nuclecapsids

Legal Events

Date Code Title Description
FB Suspension of granting procedure